Works matching IS 13524585 AND DT 2019 AND VI 25 AND IP 2


Results: 20
    1

    Corrigendum.

    Published in:
    2019
    Publication type:
    Correction Notice
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.

    Published in:
    Multiple Sclerosis Journal, 2019, v. 25, n. 2, p. 235, doi. 10.1177/1352458517740641
    By:
    • Agius, Mark A.;
    • Barron, Gerard;
    • Klodowska-Duda, Gabriela;
    • Maciejowski, Maciej;
    • Potemkowski, Andrzej;
    • Jing Li;
    • Wesley, Jacob;
    • Madani, Soraya;
    • Katz, Eliezer;
    • Flor, Armando;
    • Patra, Kaushik
    Publication type:
    Article
    11
    12
    13
    14

    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.

    Published in:
    Multiple Sclerosis Journal, 2019, v. 25, n. 2, p. 196, doi. 10.1177/1352458517740216
    By:
    • Bsteh, Gabriel;
    • Hegen, Harald;
    • Amprosi, Matthias;
    • Berek, Klaus;
    • Ladstätter, Felix;
    • Wurth, Sebastian;
    • Auer, Michael;
    • Di Pauli, Franziska;
    • Deisenhammer, Florian;
    • Berger, Thomas;
    • Teuchner, Barbara
    Publication type:
    Article
    15
    16
    17
    18
    19
    20

    Corrigendum.

    Published in:
    2019
    Publication type:
    Correction Notice